At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results of the multi-arm phase 1 TATTON trial, which evaluated the mutant-selective EGFR tyrosine kinase inhibitor, AZD9291, combined with MEDI4736 (anti-PD-L1 monoclonal antibody), savolitinib (MET inhibitor) or selumetinib (MEK1/2 inhibitor) in patients with EGFR-mutant lung cancer.
TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer
10th July 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?